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SP1: Synthesis and characterization of Lipopeptide
The lipopeptide LP [CH3(CH2)16CONH-GPQGIAGQR(GPO)4GG-COOH] was synthesized by employing microwave assisted solid phase peptide synthesizer (Liberty, CEM Corporation, Matthews, SC) by following the protocol previously established in our laboratory 19 . The lipopeptide was purified by reverse phase HPLC (Shimadzu Scientific Instruments) using a diphenyl semi-preparatory column (Grace Vydac, 300 Å pore diameter silica, 5 μm particle size, 10 mm × 250 mm) as the stationary phase. A linear gradient (0−70%) of acetonitrile (with 0.1% trifluoroacetic acid) in water (with 0.1% trifluoroacetic acid) was used at a flow rate of 8 mL/min over 60 min. The chromatogram was recorded at 235 nm using a UV detector. After freeze drying the eluents, the peptide was characterized employing MALDI-TOF mass spectrometry with an AB 4800 MALDI TOF/TOF mass analyzer. An observed mass of 2332.3 Da in MALDI spectra confirmed the LP (calculated mass: 2332.2 Da). The collagen mimetic triple helical structure of the lipopeptide was assessed by CD spectrometry employing a Jasco J-815 CD spectrometer with a quartz cuvette of 1 mm path length. The positive peak at 222 nm and the negative peak at 198 nm confirmed the triple helical structure of collagen mimetic peptide. For the CD spectroscopic studies, 32 accumulations were recorded for each spectra.
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SP2: Synthesis of POPE-SPDP derivative
To a stirred solution of POPE (100 mg, 0.139 mmol) in dichloromethane (10 mL 
SP3: Synthesis of POPE-S-S-PEG
The product obtained in the previous reaction (35 mg, 0.038 mmol) was reacted with PEG-SH 13.90, 14.31, 19.27, 22.87, 25.06, 27.43, 29.51, 29.56, 29.87, 29.93, 32.10, 34.3, 59.22, 70.75, 72.13, 129.87, 130.168 . MALDI mass spectra also confirmed the conjugation of PEG ( Figure S1 ).
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SC1: Calculation for percent entrapment of gemcitabine
To calculate percent drug entrapment, absorbance of liposomes was measured at 268nm (ƛmax of gemcitabine) before passing through Sephadex column (A1) and after collecting the eluent (A2). Dilution factor (d) was taken into consideration while calculating percent entrapment of the drug.
= 1 − 2 1 × 100
SC2: Calculation for amount of gemcitabine entrapped in nanovesicles
Gemcitabine was loaded in nanovesicles by pH gradient method. Citrate buffer (pH 4) encapsulated nanovesicles were incubated with gemcitabine, maintaining lipid:drug ratio of 10:1 (for example, 1 mg lipid containing vesicles were incubated with 0.1 mg of gemcitabine). Percent drug entrapment was calculated by using equation given in SC1. Percent entrapment of 50% indicated that 50 µg of gemcitabine is encapsulated in nanovesicles containing 1 mg equivalent of lipid. Figure S4 . Effect of MMP-9 and GSH treatments on the size of nanovesicles at 37 ºC. Nanovesicles treated with MMP-9 (2 µM) and GSH (50 µM) showed significant increase in size in 24 hours (magenta triangles). Nanovesicles receiving only MMP-9 (2 µM) treatment also showed some increase in size within 24 hours (blue triangles). No substantial change in size was observed when nanovesicles received no treatment (black squares). Treatment with GSH (50 µM) showed a slight decrease in size over 24 hours (red circles). Figure S5 . Toxicity of nanovesicles. Nanovesicles did not show any toxicity when incubated with MIAPaca-2 cells for 72 hours
